India's Sun Pharmaceutical meets Feb. 1 deadline for U.S. imatinib launch

Mumbai-based Sun Pharmaceutical Industries met an in-house deadline of Feb. 1 to launch sales of generic Gleevec/Glivec (imatinib) in the U.S. that included a savings card program to cut the co-payment out-of-pocket costs for the cancer treatment with certain pharmacies. "The savings card will reduce patient's co-payment (out-of-pocket) to $10," the company said in a release. "In line with its philosophy of putting patients first, Sun Pharma's Imatinib Mesylate Savings Card will also offer patients additional savings benefit of up to $700 for a 30-day fill to offset any additional out-of-pocket cost should they be required to meet their deductible or co-insurance." Sun, as first to file, now starts a 180-day marketing exclusivity period on the generic that puts it head-to-head with Novartis ($NVS). On the Jan. 27 earnings call, Novartis said it fully expected Sun to meet the launch date. Release

Suggested Articles

New legal complaints focus on eight Sanofi executives, most of them with local management titles, and 15 managers at distributor Zuellig Pharma.

A self-proclaimed former employee at Novartis’ Beijing office accused the Swiss drugmaker of expensing fake academic events to offer kickbacks to doctors.

A decree includes tax incentives for certain generic drugmakers and uniform insurance standards that apply to both branded drugs and generics.